Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Bernard Séguin, DVM, MS, dip ACVS, ACVS Founding Fellow, Surgical Oncology
Course Open: January 18-February 25, 2022
Real Time Sessions (RTS): Tuesdays January 25, February 1, 8, and 15, 2022; 8:00-10:00 pm ET (USA) World Clock Converter
Total CE Credit: 8
RACE Category: 8 hours Medical Skip to Enrollment Course Information:
The course will cover the different goals that can be achieved with surgery when removing a tumor. It will go over the factors that are taken into account in deciding what is the best goal for a particular patient. These goals will in turn determine the aggressiveness of the surgery. Therefore the “doses” of surgery will be reviewed to understand the different levels of aggressiveness. The principles of to how remove a tumor will be covered in light of the biology of the tumors. Learning Objectives:
Upon completion of the course, the participant should be able to
- understand the role of the clinician and pathologist and their respective duties when submitting a biopsy.
- recognize which information is a must on a pathology report.
- describes times when more information is needed.
- discuss the rationale use of specialized panels and markers.
- understand the possible goals of surgery and how to decide which goal is best.
- understand the different “doses” of surgery and when to use each one.
- understand the rationale for principles of how to remove a tumor.
- better understand the anatomy of the liver.
- discuss primary hepatic tumors:
- Morphology
- Tumors types and frequency
- Signalment and clinical signs
- Clinical staging including bloodwork and imaging
- Therapy to include surgical aspects and medical aspects (chemotherapy, radiation therapy, interventional techniques and novel therapies)
- Review surgical techniques to remove hepatic tumors
- discuss transitional cell carcinoma:
- Etiology, signalment, and clinical signs
- Staging and diagnosis
- discuss primary lungs tumors in regards to:
- Etiology
- Tumor types
- Clinical staging including advanced imaging
- Diagnosis
- Treatment (Surgical and Medical)
- Review the different approaches to a thoracotomy
- Review for lung lobectomy and discussion of pneumonectomy
- Tracheobronchial lymph node excision for staging purposes
- Role of chemotherapy
- Prognosis
- discuss thymoma (canine and feline):
- Clinical signs
- Diagnostic workup
- Treatment:
- Surgical excision of thymomas
- Role of Radiation therapy
- Prognosis
- understand the best mechanisms for obtaining a diagnosis of an MCT or STS
- understand the staging options for dogs with MCT or STS
- understand and apply the current standard of care surgical options for dogs with MCT or STS
- evaluate a histopathologic report from a dog with MCT or STS to then make the best additional treatment recommendations (e.g. radiation, chemotherapy, Palladia, etc.) vs no additional treatment
- discuss treatment options, including surgical, medical (NSAIDs, chemotherapy, tyrosine kinase inhibitors), radiation therapy and interventional techniques.
Accreditation: This course is approved for 8 hours of continuing education credit by RACE for veterinarians. (RACE 20-866797) Course Agenda: Week 1 (Real Time Session January 25, 2022): Surgical Oncology and Histopathology
Week 2 (Real Time Session February 1, 2022): Multimodal Approach to Intra-Abdominal Neoplasia
This session will go over hepatocellular carcinoma and bladder transitional cell carcinoma: their diagnosis, treatment options, and prognosis. Week 3 (Real Time Session February 8, 2022): Multimodal Approach to Intrathoracic Neoplasia
This session will go over primary lung tumors, thymomas, and chemodectomas: their diagnosis, treatment options, and prognosis. Week 4 (Real Time Session February 15, 2022): Multimodal Approach to Mast Cell and Soft Tissue Neoplasia
This final session will review the biologic behaviors of mast cell tumors (MCT) and soft tissue sarcomas (STS) in dogs. We will approach the course by discussing the diagnostic process, the staging options for the patient and then delve into surgical recommendations for these tumors. We will then take various post-operative histopathologic variables into account for possible additional radiation and/or medical oncology treatment recommendations. Successful completion (scoring 80% or better) on the end-of-course test is required to earn a certificate of completion for the course. To learn more about the requirements for earning a CE certificate, please refer to Receiving Your CE Credit and Course Completion Certificate. Course Materials: Course materials will be available in the course library prior to each Real Time Session.
Required Textbook(s): There is no required textbook for this course.
Enrollment is closed.
Tuition: Member $184 ($166 early bird special if enrolled by January 4, 2022)
Non-Member $292 ($263 early bird special if enrolled by January 4, 2022)
Prices are listed in US dollars. *To ensure participants are ready and prepared for classes, enrollment will close on January 25, 2022 at 5 pm ET (USA) or when the maximum number of participants is reached. *For more information on how online CE works, see the Participant Resource Center.
- Enrollment qualifications: VIN CE courses are open to VIN member and non-member veterinarians. Veterinarians enrolling in a VSPN CE course must be a VIN member. Veterinary support staff must be a VSPN member to enroll in a VSPN CE or a VIN CE course open to VSPN member enrollment.
- Each enrollee must be able to receive emails from @vspn.org and @vin.com addresses. Email is our major form of communication with participants; personal emails are highly recommended rather than clinic/hospital email addresses.
- For further assistance call 800-846-0028 ext. 797 or email CEonVIN. Please include the course title, your full name, and contact information in your correspondence.
VIN Education Director VIN CE Services: CEonVIN
800-846-0028 or 530-756-4881; ext. 797
or direct line to VIN/VSPN from the United Kingdom: 01 45 222 6154
or direct line to VIN/VSPN from Australia: 02 6145 2357